SMITH+NEPHEW ADR5 DL-20/2
Certificado de depósito · US83175M2052 · SNN · 939163 (XNYS)
30,27 USD
06.06.2025 19:59
Cotizaciones actuales de SMITH+NEPHEW ADR5 DL-20/2
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() NYSE |
SNN
|
USD
|
06.06.2025 19:59
|
30,27 USD
| 30,31 USD
-0,13 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
0,00 % | 4,56 % | 6,89 % | 1,58 % | 19,31 % | 14,92 % | -31,58 % |
Profil de l'entreprise pour SMITH+NEPHEW ADR5 DL-20/2 Certificat de dépôt
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Données de l'entreprise
Nom SMITH+NEPHEW ADR5 DL-20/2
Société Smith & Nephew plc
Symbole SNN
Site web
https://www.smith-nephew.com
Marché d'origine
NYSE

WKN 939163
ISIN US83175M2052
Type de titre Certificat de dépôt
Secteur Healthcare
Industrie Medical - Devices
PDG Dr. Deepak S. Nath Ph.D.
Capitalisation boursière 11 Mrd.
Pays Royaume-Uni
Devise USD
Employés 17,3 T
Adresse Building 5, WD18 8YE Watford
Date d'introduction en bourse 1999-11-16
Fractionnements d'actions
Date | Fractionnement |
---|---|
15.10.2014 | 2499:1000 |
16.12.2003 | 2:1 |
07.08.2000 | 9:11 |
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | NPWA.F |
NYSE | SNN |
Autres actions
Les investisseurs qui détiennent SMITH+NEPHEW ADR5 DL-20/2 ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.